Patents Assigned to PPL Therapeutics (Scotland) Ltd
  • Patent number: 7030289
    Abstract: The present invention relates to the stabilization of milk from transgenic animals. In particular, the invention relates to the protection of proteins (e.g. fibrinogen) expressed in milk from transgenic animals by co-expression of a serine proteinase inhibitor (e.g., ?1-antitrypsin) in the milk of the transgenic animals.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: April 18, 2006
    Assignee: PPL Therapeutics (Scotland) Ltd
    Inventors: Ian Robert Cottingham, Graham Edward McCreath
  • Publication number: 20030167477
    Abstract: A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.
    Type: Application
    Filed: December 21, 2001
    Publication date: September 4, 2003
    Applicant: PPL Therapeutics (Scotland) Ltd.
    Inventors: Ian Robert Cottingham, Graham Edward McCreath
  • Publication number: 20030145339
    Abstract: A method of producing a substance comprising a peptide, involves incorporating a DNA sequence coding for the peptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The substance may be an (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The substance will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.
    Type: Application
    Filed: September 25, 2002
    Publication date: July 31, 2003
    Applicant: PPL Therapeutics (Scotland) Ltd.
    Inventors: Anthony John Clark, Richard Lathe
  • Patent number: 5476995
    Abstract: A method of producing a proteinaceous compound, involves incorporating a DNA sequence coding for polypeptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The proteinaceous compound may be a (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The proteinaceous compound will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.
    Type: Grant
    Filed: August 18, 1992
    Date of Patent: December 19, 1995
    Assignee: PPL Therapeutics (Scotland) Ltd.
    Inventors: Anthony J. Clark, Richard Lathe